AffaMed Therapeutics Announces Positive Topline Results from Real-World Study in China Evaluating Dextenza in Patients after Cataract Surgery

AffaMed Therapeutics announced positive topline results from the real-world study conducted in the Boao Lecheng Pilot Zone in Hainan, China, to evaluate the safety and efficacy of Dextenza (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain following cataract surgery.

• The trial met its primary endpoint, with Dextenza demonstrating a significant reduction of ocular inflammation as measured by the absence of anterior chamber cells (i.e. score of "0") in the study eye on Day 14 after cataract surgery
• The trial also met its secondary endpoint, demonstrating a significant reduction of ocular pain on Day 8
• Dextenza was well-tolerated and had a favorable safety profile consistent with all prior trials

"We are thrilled to announce the positive topline results from our real-world study in cataract surgery patients," Dr. Dayao Zhao, CEO of AffaMed, said in a company news release. "Dextenza shows great efficacy and safety in Chinese patients, and this is a significant milestone for AffaMed in advancing this late-stage program towards registration in Mainland China."

In October 2020, AffaMed Therapeutics entered into a licensing agreement with Ocular Therapeutix for the development and commercialization of Dextenza in Greater China, South Korea, and certain ASEAN markets. Dextenza is approved in the US and Macau SAR for the treatment of ocular inflammation and pain following ophthalmic surgery, and ocular itching associated with allergic conjunctivitis.

AffaMed is developing Dextenza to become the first sustained-release intracanalicular insert in China delivering a preservative-free dose of dexamethasone for up to 30 days with a single administration. This product offers patients significant benefits and convenience vs. current standard of care requiring multiple daily administrations of eyedrops.